Top

Published in:

01-10-2018 | Original Article

The first two confirmed sub-Saharan African families with germline TP53 mutations causing Li-Fraumeni syndrome

Authors: Shelley Macaulay, Quintin Clive Goodyear, Mia Kruger, Wenlong Chen, Fahmida Essop, Amanda Krause

Published in: Familial Cancer | Issue 4/2018

Abstract

Li-Fraumeni syndrome is a rare inherited cancer syndrome characterised by the early onset of specific cancers. Li-Fraumeni syndrome (LFS) is associated with germline mutations in the tumour suppressor gene, TP53. This study reports the first cases of molecularly confirmed LFS germline mutations in sub-Saharan Africa. Three black African patients, all with LFS-associated cancers, were seen through the Clinical and Counselling Section of the Division of Human Genetics at the National Health Laboratory Service and University of the Witwatersrand in Johannesburg, South Africa, during 2011–2012. All three patients (two were related) were recruited into this research study. Sequence analysis of the coding region of the TP53 gene identified a Class IV (likely pathogenic) variant, c.326T > C (p.Phe109Ser), in the two related patients, and a known pathogenic mutation, c.1010G > A (p.Arg337His), also referred to as the Brazilian founder mutation, in the other patient. A confirmed diagnosis in these patients will assist in tailored medical management (it is recommended that individuals carrying a germline TP53 mutation avoid radiotherapy as this might cause secondary radiotherapy-induced malignancies) and in addition, genetic testing of at-risk family members can be offered. Very little is known and documented on LFS in African individuals. Despite the small number of patients in this study, the results support the need for diagnostic genetic testing for LFS in South Africa.

Available only for authorised users

American Cancer Society (2011) Cancer in Africa. American Cancer Society, Atlanta

Anand P, Kunnumakara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS et al (2008) Cancer is a preventable disease that requires major lifestyle changes. Pharm Res 25(9):2097–2116CrossRefPubMedPubMedCentral

Oluwagbemiga LA, Oluwole A, Kayode AA (2012) Seventeen years after BRCA1: what is the BRCA mutation status of the breast cancer patients in Africa?: a systematic review. Springerplus 1(1):83. https://doi.org/10.1186/2193-1801-1-83 CrossRefPubMedPubMedCentral

Francies FZ, Wainstein T, De Leeneer K, Cairns A, Murdoch M, Nietz S et al (2015) BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer. BMC Cancer 15:912. https://doi.org/10.1186/s12885-015-1913-6 CrossRefPubMedPubMedCentral

Li FP, Fraumeni JF Jr (1969) Soft-tissue sarcomas, breast cancer, and other neoplasms: a familial syndrome? Ann Intern Med 71(4):747–752CrossRefPubMed

Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA et al (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48(18):5358–5362PubMed

Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M et al (2001) Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 20(34):4621–4628. https://doi.org/10.1038/sj.onc.1204621 CrossRefPubMed

Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M et al (2015) Revisiting Li-fraumeni syndrome from TP53 mutation carriers. J Clin Oncol 33(21):2345–2352. https://doi.org/10.1200/JCO.2014.59.5728 CrossRefPubMed

Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH et al (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250(4985):1233–1238CrossRefPubMed

10.

Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM et al (1989) Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244(4901):217–221CrossRefPubMed

11.

Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP et al (2005) p53 isoforms can regulate p53 transcriptional activity. Genes Dev 19(18):2122–2137. https://doi.org/10.1101/gad.1339905 CrossRefPubMedPubMedCentral

12.

Bouaoun L, Sonkin D, Ardin M, Hollstein M, Byrnes G, Zavadil J et al (2016) TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum Mutat 37(9):865–876. https://doi.org/10.1002/humu.23035 CrossRefPubMed

13.

Hung J, Mims B, Lozano G, Strong L, Harvey C, Chen TT et al (1999) TP53 mutation and haplotype analysis of two large African American families. Hum Mutat 14(3):216–221CrossRefPubMed

14.

Olivier M, Hollstein M, Hainaut P (2010) TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2(1):a001008. https://doi.org/10.1101/cshperspect.a001008 CrossRefPubMedPubMedCentral

15.

Pavletich NP, Chambers KA, Pabo CO (1993) The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev 7(12B):2556–2564CrossRefPubMed

16.

Bougeard G, Sesboue R, Baert-Desurmont S, Vasseur S, Martin C, Tinat J et al (2008) Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet 45(8):535–538. https://doi.org/10.1136/jmg.2008.057570 CrossRefPubMed

17.

Amadou A, Waddington Achatz MI, Hainaut P (2018) Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome. Curr Opin Oncol 30(1):23–29. https://doi.org/10.1097/CCO.0000000000000423 CrossRefPubMed

18.

Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):1215CrossRefPubMedPubMedCentral

19.

Kearse M, Moir R, Wilson A, Stones-Havas S, Cheung M, Sturrock S et al (2012) Geneious basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics 28(12):1647–1649. https://doi.org/10.1093/bioinformatics/bts199 CrossRefPubMedPubMedCentral

20.

Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM et al (2001) dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29(1):308–311CrossRefPubMedPubMedCentral

21.

Stenson PD, Mort M, Ball EV, Howells K, Phillips AD, Thomas NS et al (2009) The human gene mutation database: 2008 update. Genome Med 1(1):13. https://doi.org/10.1186/gm13 CrossRefPubMedPubMedCentral

22.

Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T et al (2016) Analysis of protein-coding genetic variation in 60,706 humans. Nature 536(7616):285–291. https://doi.org/10.1038/nature19057 CrossRefPubMedPubMedCentral

23.

Landrum MJ, Lee JM, Benson M, Brown G, Chao C, Chitipiralla S et al (2016) ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res 44(D1):D862-8. https://doi.org/10.1093/nar/gkv1222 CrossRefPubMed

24.

McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F (2010) Variant effect predictor. BMC Bioinformatics 26:2069–2070CrossRef

25.

Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P et al (2010) A method and server for predicting damaging missense mutations. Nat Methods 7(4):248–249. https://doi.org/10.1038/nmeth0410-248 CrossRefPubMedPubMedCentral

26.

Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4(7):1073–1081. https://doi.org/10.1038/nprot.2009.86 CrossRefPubMed

27.

The UniProt Consortium (2012) Reorganizing the protein space at the universal protein resource (UniProt). Nucleic Acids Res 40(Database issue):D71–D75. https://doi.org/10.1093/nar/gkr981 CrossRef

28.

Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J (2014) A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 46(3):310–315. https://doi.org/10.1038/ng.2892 CrossRefPubMedPubMedCentral

29.

Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W et al (2011) Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol 7:539. https://doi.org/10.1038/msb.2011.75 CrossRefPubMedPubMedCentral

30.

Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R et al (2003) Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 100(14):8424–8429. https://doi.org/10.1073/pnas.1431692100 CrossRefPubMedPubMedCentral

31.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405–424. https://doi.org/10.1038/gim.2015.30 CrossRefPubMedPubMedCentral

32.

Pinto EM, Ribeiro RC, Figueiredo BC, Zambetti GP (2011) TP53-associated pediatric malignancies. Genes Cancer 2(4):485–490. https://doi.org/10.1177/1947601911409745 CrossRefPubMedPubMedCentral

33.

Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, Lafferty AR et al (2001) An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA 98(16):9330–9335. https://doi.org/10.1073/pnas.161479898 CrossRefPubMedPubMedCentral

34.

Bougeard G, Limacher JM, Martin C, Charbonnier F, Killian A, Delattre O et al (2001) Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome. J Med Genet 38(4):253–257CrossRefPubMedPubMedCentral

35.

Herrmann LJ, Heinze B, Fassnacht M, Willenberg HS, Quinkler M, Reisch N et al (2012) TP53 germline mutation in adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab 97(3):E476-85CrossRefPubMed

36.

Figueiredo BC, Sandrini R, Zambetti GP, Pereira RM, Cheng C, Liu W et al (2006) Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. J Med Genet 43(1):91–96. https://doi.org/10.1136/jmg.2004.030551 CrossRefPubMed

37.

Cury NM, Ferraz VE, Silva WA (2014) Jr. TP53 p.R337H prevalence in a series of Brazilian hereditary breast cancer families. Hered Cancer Clin Pract 12(1):8. https://doi.org/10.1186/1897-4287-12-8 CrossRefPubMedPubMedCentral

38.

Borges LM, Ayres FM (2015) R337H mutation of the TP53 gene as a clinical marker in cancer patients: a systematic review of literature. Genet Mol Res 14(4):17034–17043. https://doi.org/10.4238/2015.December.16.4 CrossRefPubMed

39.

Curto JC, Soulodre-La France R (2005) Introduction: Interconnections between African and the Americas during the era of the slave trade. In: Curto JC, Soulodre-La France R (eds) Africa and the Americas: interconnections during the slave trade. Africa World Press, Trenton

40.

Wasserman JD, Zambetti GP, Malkin D (2012) Towards an understanding of the role of p53 in adrenocortical carcinogenesis. Mol Cell Endocrinol 351(1):101–110. https://doi.org/10.1016/j.mce.2011.09.010 CrossRefPubMed

41.

Gonzalez KD, Buzin CH, Noltner KA, Gu D, Li W, Malkin D et al (2009) High frequency of de novo mutations in Li-Fraumeni syndrome. J Med Genet 46(10):689–693. https://doi.org/10.1136/jmg.2008.058958 CrossRefPubMed

42.

Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ et al (2009) Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27(8):1250–1256. https://doi.org/10.1200/JCO.2008.16.6959 CrossRefPubMed

Title: The first two confirmed sub-Saharan African families with germline TP53 mutations causing Li-Fraumeni syndrome
Authors: Shelley Macaulay
Quintin Clive Goodyear
Mia Kruger
Wenlong Chen
Fahmida Essop
Amanda Krause
Publication date: 01-10-2018
Publisher: Springer Netherlands
Published in: Familial Cancer / Issue 4/2018
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-018-0075-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2018

Metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis

Response to letter to editor regarding published article—metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis

Haplotype analysis suggest that the MLH1 c.2059C > T mutation is a Swedish founder mutation

Commentary: PREMM5 threshold of 2.5% is recommended to improve identification of PMS2 carriers

Correlation of IL-31 gene polymorphisms with susceptibility and clinical recurrence of bladder cancer

Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk

Keynote webinar | Spotlight on antibody–drug conjugates in cancer